Salvage radiotherapy following radical prostatectomy

International Journal of Urology : Official Journal of the Japanese Urological Association
Venu ChalasaniJonathan I Izawa

Abstract

Recurrent disease following radical prostatectomy will occur in approximately 20% of patients, for whom the therapeutic options include surveillance, salvage radiotherapy, or hormonal therapy. This review will focus on the evidence for salvage radiotherapy. Efficacy results of 30-50% have been reported from multiple retrospective series, with minimal morbidity. Unfortunately there are no randomized or prospective studies in this area. Results of salvage radiotherapy improve when given earlier, ideally with the serum prostate-specific antigen < 1 ng/mL. Other positive prognosticators are positive margins at radical prostatectomy, longer prostate-specific antigen doubling times, lower radical prostatectomy Gleason scores, and the absence of lymph node metastases. Current standard dosage is 64 Gy or slightly higher, although the optimal dosage has yet to be defined with prospective randomized trials. Salvage radiotherapy can provide a durable response when given early, and patients with recurrent disease should be considered for treatment or enrolment in clinical trials.

References

May 1, 1992·Urology·M AllenM S Soloway
Jul 1, 1997·International Journal of Radiation Oncology, Biology, Physics·M M MorrisW U Shipley
Oct 6, 1997·International Journal of Radiation Oncology, Biology, Physics·M J ZelefskyS A Leibel
Oct 23, 1997·International Journal of Radiation Oncology, Biology, Physics·C H CraneM D Kelly
Jan 9, 1998·International Journal of Radiation Oncology, Biology, Physics·Z PetrovichD G Skinner
May 20, 1998·International Journal of Radiation Oncology, Biology, Physics·J F RaymondK J Russell
Nov 7, 1998·International Journal of Radiation Oncology, Biology, Physics·R K ValicentiB W Corn
Dec 10, 1998·Journal of Surgical Oncology·M V TefilliJ E Pontes
May 11, 1999·JAMA : the Journal of the American Medical Association·C R PoundP C Walsh
Sep 7, 2000·International Journal of Radiation Oncology, Biology, Physics·M S AnscherR Dodge
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A K LeventisK M Slawin
Apr 11, 2001·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·C CattonM Milosevic
Apr 18, 2001·European Urology·L VanuytselL Baert
Nov 3, 2001·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·C ParkerC Catton
May 7, 2002·Urology·Ramona MayerArnulf Hackl
May 23, 2002·International Journal of Radiation Oncology, Biology, Physics·Richard ChooGerrit DeBoer
Jul 26, 2002·Urology·Danny Y SongTheodore L DeWeese
Nov 7, 2002·International Journal of Radiation Oncology, Biology, Physics·John A KalapurakalRamananda M Shetty
Dec 24, 2002·Prostate Cancer and Prostatic Diseases·S EgawaS Baba
Feb 28, 2003·International Journal of Radiation Oncology, Biology, Physics·Gillian M DuchesneRoss Snow
Jun 6, 2003·International Journal of Radiation Oncology, Biology, Physics·N TaylorA Pollack

❮ Previous
Next ❯

Citations

Feb 4, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Lori E LowesTracy Sexton
Oct 27, 2015·International Journal of Urology : Official Journal of the Japanese Urological Association·Wan SongHyun Moo Lee
Dec 23, 2011·International Journal of Urology : Official Journal of the Japanese Urological Association·Toyoaki UchidaToshiro Terachi
Jul 28, 2016·Clinical Oncology : a Journal of the Royal College of Radiologists·C J JinT P Hanna

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Urology
Axel HeidenreichEuropean Association of Urology
JAMA : the Journal of the American Medical Association
Andrew J StephensonKevin M Slawin
International Journal of Epidemiology
Danella M Hafeman, Sharon Schwartz
© 2022 Meta ULC. All rights reserved